Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

4 analysts have shared their evaluations of Septerna SEPN during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their ...

Septerna (NASDAQ:SEPN – Get Free Report) is projected to announce its Q1 2025 earnings results on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for ...

Get the latest Septerna, Inc. (SEPN) stock news and headlines to help you in your trading and investing decisions.

Fintel reports that on June 23, 2025, HC Wainwright & Co. initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy recommendation. Analyst Price Forecast Suggests 85.10% Upside As of June 20 ...

Novo Nordisk and Septerna will jointly carry out research on the candidates from discovery to development candidate selection, with the Danish pharma group taking over responsibility as they ...

Septerna Inc (Symbol: SEPN) options are showing a volume of 3,219 contracts thus far today.

Septerna Inc. is listed on the CBOE trading with ticker code SEPN.US. It has a market capitalisation of $466.53m, with approximately 44.56m shares in issue. Over the last year, Septerna Inc. share ...